Journal
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
Volume 17, Issue 7, Pages 1671-1681Publisher
IVYSPRING INT PUBL
DOI: 10.7150/ijbs.57964
Keywords
MUC3A; non-small cell lung cancer; EGFR; PD-L1
Categories
Funding
- National Natural Science Foundation of China [81773236, 81800429, 81972852]
- Key Research & Development Project of Hubei Province [2020BCA069]
- Nature Science Foundation of Hubei Province [2020CFB612]
- Health Commission of Hubei Province Medical Leading Talent Project
- Young & Middle-Aged Medical Backbone Talents of Wuhan [WHQG201902]
- Application Foundation Frontier Project of Wuhan [2020020601012221]
- Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund [znpy2019001, znpy2019048, ZNJC201922]
- Chinese Society of Clinical Oncology TopAlliance Tumor Immune Research Fund [Y-JS2019-036]
Ask authors/readers for more resources
The transmembrane mucin MUC3A induces PD-L1 expression in NSCLC, promoting immune escape, while downregulation of MUC3A enhances the effects of TKIs in EGFR-mutant NSCLC. Knocking down MUC3A reduces PD-L1 expression by downregulating the activation of the PI3K/Akt and MAPK pathways. In vitro, the combination of MUC3A knockdown and TKIs in EGFR-mutant NSCLC cells has a synergistic effect on inhibiting proliferation and promoting apoptosis.
The immune checkpoint ligand programmed death-ligand 1 (PD-L1) and the transmembrane mucin (MUC) 3A are upregulated in non-small cell lung cancer (NSCLC), contributing to the aggressive pathogenesis and poor prognosis. Here, we report that knocking down the oncogenic MUC3A suppresses the PD-L1 expression in NSCLC cells. MUC3A is a potent regulator of epidermal growth factor receptor (EGFR) stability, and MUC3A deficiency downregulates the activation of the PI3K/Akt and MAPK pathways, which subsequently reduces the expression of PD-L1. Furthermore, knockdown of MUC3A and tyrosine kinase inhibitors (TKIs) in EGFR-mutant NSCLC cells play a synergistic effect on inhibited proliferation and promoted apoptosis in vitro. In the BALB/c nude mice xenograft model, MUC3A deficiency enhances EGFR-mutated NSCLC sensitivity to TKIs. Our study shows that transmembrane mucin MUC3A induces PD-L1, thereby promoting immune escape in NSCLC, while downregulation of MUC3A enhances TKIs effects in EGFR-mutant NSCLC. These findings offer insights into the design of novel combination treatment for NSCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available